- Home
- SLXN vs ALLR Comparison
SLXN vs ALLR Comparison
Compare SLXN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- ALLR
- Stock Information
- Founded
- SLXN 2008
- ALLR 2004
- Country
- SLXN Israel
- ALLR United States
- Employees
- SLXN N/A
- ALLR N/A
- Industry
- SLXN
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- ALLR Health Care
- Exchange
- SLXN NYSE
- ALLR Nasdaq
- Market Cap
- SLXN 4.3M
- ALLR 4.0M
- IPO Year
- SLXN N/A
- ALLR N/A
- Fundamental
- Price
- SLXN $0.99
- ALLR $0.88
- Analyst Decision
- SLXN Strong Buy
- ALLR
- Analyst Count
- SLXN 1
- ALLR 0
- Target Price
- SLXN $5.00
- ALLR N/A
- AVG Volume (30 Days)
- SLXN 952.7K
- ALLR 2.6M
- Earning Date
- SLXN 05-21-2025
- ALLR 05-13-2025
- Dividend Yield
- SLXN N/A
- ALLR N/A
- EPS Growth
- SLXN N/A
- ALLR N/A
- EPS
- SLXN N/A
- ALLR N/A
- Revenue
- SLXN N/A
- ALLR N/A
- Revenue This Year
- SLXN N/A
- ALLR N/A
- Revenue Next Year
- SLXN N/A
- ALLR N/A
- P/E Ratio
- SLXN N/A
- ALLR N/A
- Revenue Growth
- SLXN N/A
- ALLR N/A
- 52 Week Low
- SLXN $0.21
- ALLR $0.68
- 52 Week High
- SLXN $13.56
- ALLR $174.00
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- ALLR 42.95
- Support Level
- SLXN N/A
- ALLR $0.91
- Resistance Level
- SLXN N/A
- ALLR $1.23
- Average True Range (ATR)
- SLXN 0.00
- ALLR 0.14
- MACD
- SLXN 0.00
- ALLR -0.01
- Stochastic Oscillator
- SLXN 0.00
- ALLR 15.31
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.